ANNOUNCEMENT FOR EUROPEAN FINANCIAL AND PHARMACEUTICAL TRADE MEDIA ONLY. Theramex Enters an Exclusive Licensing Agreement with Asieris for CEVIRA® (hexaminolevulinate hydrochloride photodynamic therapy system, APL-1702) subject to certain conditions, a Potential First-in-Class Non-Surgical Treatment for Cervical Precancerous Lesions in Europe Agreement is expected to strengthen Theramex’s women’s health pipeline and expands its presence in gynaecology … Continue reading Theramex Enters an Exclusive Licensing Agreement with Asieris for CEVIRA^®